Turn Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
TTRX$9.92+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | |||
|---|---|---|---|
| 2026 · 2025 | |||
| Cash flows from operating activities: | |||
| Net loss | $(970,972) | $(328,547) | |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| Amortization expense | 14,451 | 12,422 | |
| Stock-based compensation expense | 280,830 | 76,597 | |
| Common stock issued in exchange for services | - | 250,000 | |
| Non-cash operating lease effect | - | (620) | |
| Net gain from change in fair value of derivative liability instruments | (697,561) | - | |
| Amortization of deferred offering cost | 477,647 | - | |
| Changes in operating assets and liabilities: | |||
| Prepaids and other current assets | (123,738) | (287,141) | |
| Accounts payable and accrued expenses | (613,464) | (20,769) | |
| Net cash used in operating activities | (1,632,807) | (298,058) | |
| Cash flows from investing activities: | |||
| Purchases of intangible assets | (12,227) | - | |
| Net cash used in investing activities | (12,227) | - | |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock, net of issuance costs | - | 998,092 | |
| Cash receipt from stock subscription receivable | 1,070,000 | - | |
| Proceeds from Avenue Capital Loan Agreement | 6,716,561 | - | |
| Net cash provided by financing activities | 7,786,561 | 998,092 | |
| Net increase (decrease) in cash and cash equivalents | 6,141,527 | 700,034 | |
| Cash and cash equivalents at beginning of the period | 5,076,144 | 872,599 | |
| Cash and cash equivalents at end of the period | $11,217,671 | $1,572,633 | |
| Supplemental disclosure of non-cash activities | |||
| Issuance of common stock under Avenue Capital Agreement | $1,050,967 | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.